Monkeypox

Monkeypox is an infectious disease caused by the monkeypox virus that can occur in certain animals including humans. Symptoms begin with fever, headache, muscle pains, swollen lymph nodes, and feeling tired. This is followed by a rash that forms blisters and crusts over. The time from exposure to onset of symptoms is around 10 days. The duration of symptoms is typically 2 to 5 weeks. Monkeypox may be spread from handling bush meat, an animal bite or scratch, body fluids, contaminated objects, or close contact with an infected person. The virus is believed to normally circulate among certain rodents in Africa. Diagnosis can be confirmed by testing a lesion for the virus's DNA. The disease can appear similar to chickenpox. The smallpox vaccine is believed to prevent infection. In 2019 a vaccine was approved for the disorder in the United States. There is no known cure. Cidofovir or brincidofovir may be useful. The risk of death in those infected is up to 10%.

https://en.wikipedia.org/wiki/Monkeypox

Seroprevalence and Risk Factors Possibly Associated with Emerging Zoonotic Vaccinia Virus in a...

Dairy farmers had high rates of orthopoxvirus seropositivity and substantial illness associated with vaccinia-like lesions.

discovered 4 months ago on Centers for Disease Control and Prevention
Phase 3 trial shows MVA vaccine likely protects against smallpox

In today's New England Journal of Medicine, researchers describe the phase 3 trial results of the newly approved modified vaccinia Ankara vaccine (MVA) and said the vaccine is safe and likely ...

discovered 4 months ago on Center for Infectious Disease Research and Policy
Rethinking Herd Immunity

On January 13, 2008, an unvaccinated seven-year-old boy returned home to San Diego from a family vacation in Switzerland. Public health officials...

discovered 4 months ago on Scientific American
Phase 3 Results of Bavarian Nordic's Smallpox Vaccine Published in The New England Journal of...

Food and Drug Administration. The vaccine, marketed as JYNNEOS(TM), is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older. "We ...

discovered 4 months ago on Market Watch
Vaccine Effective Against Smallpox in Military: Pivotal Trial

(TM), was developed by Bavarian Nordic (Kvistgard, Denmark) and approved by the U.S. Food and Drug Administration on September 24 for the prevention of smallpox and monkeypox

discovered 4 months ago on Medscape
Edited Transcript of BAVA.CO earnings conference call or presentation 7-Nov-19 1:00pm GMT

We have our Ebola program where we've just filed for approval in Europe, which we expect approval next year; our smallpox vaccine has entered Phase III; the RSV vaccine where we've finalized ...

discovered 4 months ago on Thomson Reuters StreetEvents via Yahoo Finance
Bavarian Nordic Announces Interim Results for the First Nine Months of 2019

Food and Drug Administration (FDA) approved JYNNEOS(TM) (MVA-BN) for protection against smallpox and monkeypox. The approval was the result of our successful, fifteen-year ...

discovered 4 months ago on Market Watch
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox...

In September, the U.S. Food and Drug Administration (FDA) approved the liquid-frozen formulation of the vaccine (under the trade name JYNNEOS(TM)) for prevention of smallpox and monkeypox ...

discovered 4 months ago on Market Watch